HUSSAIN IQBAL J 4
4 · Centessa Pharmaceuticals plc · Filed Oct 16, 2025
Insider Transaction Report
Form 4
HUSSAIN IQBAL J
Chief Legal Officer
Transactions
- Sale
Ordinary Shares
2025-10-15$22.41/sh−6,000$134,439→ 105,386 total - Exercise/Conversion
Ordinary Shares
2025-10-15$5.84/sh+6,000$35,040→ 111,386 total - Exercise/Conversion
Share Option (right to buy)
2025-10-15−6,000→ 227,559 totalExercise: $5.84Exp: 2031-02-19→ Ordinary Shares (6,000 underlying)
Holdings
- 5,500(indirect: By Spouse)
Ordinary Shares
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $22.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.